Sign Out
Care should be taken when co-administering known strong CYP3A4 inhibitors (e.g. Ketoconazole, Ritonavir), as there is potential for increased systemic exposure to Fluticasone propionate.
Both non-selective and selective beta-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use.
Due to the very low plasma concentrations achieved after inhaled dosing clinically significant drug interactions are unlikely.
Continue with Google